Amanda L. Brink, DNP, APRN, FNP-BC, AOCNP, discusses the trial design of Beamion LUNG-2, a randomized phase 3 trial of zongertinib versus standard of care in patients with locally advanced or metastatic NSCLC harboring HER2 tyrosine kinase domain (TKD) mutations. She discusses the role of nurses in clinical trials, including providing essential monitoring and support to patients during their trial participation.
Amanda L. Brink, DNP, APRN, FNP-BC, AOCNP
Advanced Practice Registered Nurse
Department of Investigational Cancer Therapeutics
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, TX
Sponsored by
